MX2022007029A - Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped. - Google Patents

Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped.

Info

Publication number
MX2022007029A
MX2022007029A MX2022007029A MX2022007029A MX2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A
Authority
MX
Mexico
Prior art keywords
host disease
versus host
graft versus
antibodies
treatment
Prior art date
Application number
MX2022007029A
Other languages
English (en)
Inventor
Peter Ordentlich
Michael Meyers
Briggs W Morrison
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of MX2022007029A publication Critical patent/MX2022007029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos de tratamiento de afecciones escleróticas y, más específicamente, a métodos de tratamiento de la enfermedad crónica de injerto contra huésped con dosis específicas de un anticuerpo anti-CSF-1R, específicamente axatilimab.
MX2022007029A 2019-12-09 2020-12-09 Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped. MX2022007029A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945842P 2019-12-09 2019-12-09
US202063110111P 2020-11-05 2020-11-05
PCT/US2020/064010 WO2021119128A1 (en) 2019-12-09 2020-12-09 Antibodies for the treatment of chronic graft versus host disease

Publications (1)

Publication Number Publication Date
MX2022007029A true MX2022007029A (es) 2022-08-15

Family

ID=76330540

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007029A MX2022007029A (es) 2019-12-09 2020-12-09 Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped.

Country Status (10)

Country Link
US (1) US20230035183A1 (es)
EP (1) EP4073100A4 (es)
JP (1) JP2023506779A (es)
KR (1) KR20220123004A (es)
CN (1) CN115298210A (es)
AU (1) AU2020401551A1 (es)
CA (1) CA3164126A1 (es)
IL (1) IL293705A (es)
MX (1) MX2022007029A (es)
WO (1) WO2021119128A1 (es)

Also Published As

Publication number Publication date
US20230035183A1 (en) 2023-02-02
WO2021119128A1 (en) 2021-06-17
AU2020401551A1 (en) 2022-06-30
EP4073100A4 (en) 2024-02-14
CA3164126A1 (en) 2021-06-17
EP4073100A1 (en) 2022-10-19
IL293705A (en) 2022-08-01
JP2023506779A (ja) 2023-02-20
CN115298210A (zh) 2022-11-04
KR20220123004A (ko) 2022-09-05

Similar Documents

Publication Publication Date Title
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EA201890175A1 (ru) Антитела к cd40
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
PH12020552229A1 (en) Il-11ra antibodies
EA201990548A1 (ru) Лечение кластерной головной боли
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
AU2018230657A8 (en) Anti-C5 antibodies and uses thereof
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
NZ767902A (en) Methods of treating ulcerative colitis
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2018014560A (es) Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
ZA202008095B (en) Humanized antibodies against psma
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA202191352A1 (ru) Контроль содержания микроэлементов-металлов во время продукции антител к cd38
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use